Abstracts tagged "Diagnostic Tests"

Abstract Number: 1266 • 2017 ACR/ARHP Annual Meeting
Geographic Variation in Use of Echocardiography at Diagnosis and Detection of Acute Cardiac Disease in Youth with Systemic Lupus Erythematosus
Joyce C. Chang¹, Andrea M. Knight², Laura M. Mercer-Rosa³, Rui Xiao⁴ and Pamela F. Weiss⁵, ¹Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Division of Rheumatology, Center for Pediatric Clinical Effectiveness & PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, ³Division of Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Child-onset systemic lupus erythematosus (SLE) is a chronic autoimmune condition with a high risk of organ damage. There are no guidelines on the use…
Abstract Number: 1368 • 2017 ACR/ARHP Annual Meeting
Small RNA Sequencing Identifies Plasma microRNA Panel for Rheumatoid Arthritis Diagnosis
Michelle J. Ormseth¹, Joseph F. Solus², Quanhu Sheng², Yan Guo², Fei Ye², Ryan Allen², Kasey Vickers² and C Michael Stein², ¹Medicine, Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Small noncoding RNAs (sRNAs), such as microRNAs (miRNAs), are regulators of biological processes and serve as important biomarkers of disease. Most previous plasma sRNA…
Abstract Number: 1371 • 2017 ACR/ARHP Annual Meeting
Development of an Adjusted Multi-Biomarker Disease Activity (MBDA) Score for Rheumatoid Arthritis (RA) That Accounts for Age, Sex and Adiposity, with Subsequent Evaluation of Ability to Predict Risk for Radiographic Damage
Jeffrey R. Curtis¹, Darl D. Flake II², Michael Weinblatt³, Nancy A. Shadick⁴, Mikkel Østergaard⁵, Merete Lund Hetland⁶, Cecilie Heegaard Brahe⁶, Yong Gil Hwang⁷, Daniel E. Furst⁸, Vibeke Strand⁹, Carol J. Etzel¹⁰, Dimitrios A. Pappas¹¹, Xingbin Wang¹², Ching Chang Hwang¹³, Eric H. Sasso¹², Alexander Gutin², Elena Hitraya¹² and Jerry S. Lanchbury², ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Myriad Genetics Inc., Salt Lake City, UT, ³Brigham and Women’s Hospital, Boston, MA, ⁴Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ⁶Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ⁷Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁸David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁹Stanford University, Palo Alto, CA, ¹⁰Departments of Epidemiology and Biostatistics, University of Texas School of Public Health, Houston, TX, ¹¹Columbia University, New York, NY, ¹²Crescendo Bioscience Inc., South San Francisco, CA, ¹³Biostatistics, Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose: The MBDA score, based on 12 serum proteins, is a validated tool for assessing disease activity in RA patients. MBDA biomarkers may be influenced…
Abstract Number: 1865 • 2017 ACR/ARHP Annual Meeting
Novel Approach to Arthritis Surveillance Suggests a Much Higher Prevalence of Arthritis Among US Adults Than Previous Estimate
S. Reza Jafarzadeh and David T. Felson, Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Current national estimates of arthritis prevalence in the United States rely on a single survey question about doctor-diagnosed arthritis from the National Health Interview…
Abstract Number: 1900 • 2017 ACR/ARHP Annual Meeting
Effect of Age and Body Mass Index (BMI) on Multi-Biomarker Disease Activity (MBDA) Score in Patients with Rheumatoid Arthritis
Kerri Ford¹, David Chernoff¹, Xingbin Wang¹, Eric H. Sasso¹, Carol J. Etzel^2,3 and Dimitrios A. Pappas^3,4, ¹Crescendo Bioscience Inc., South San Francisco, CA, ²Departments of Epidemiology and Biostatistics, University of Texas School of Public Health, Houston, TX, ³Corrona, LLC, Southborough, MA, ⁴Columbia University, New York, NY
Background/Purpose: We evaluated the associations between MBDA score and age and between MBDA score and BMI in patients with rheumatoid arthritis (RA). These relationships may…
Abstract Number: 56 • 2017 Pediatric Rheumatology Symposium
Prevalence of Serum 14-3-3η in Juvenile Idiopathic Arthritis
Iris Reyhan¹, Olga S. Zhukov², Robert J. Lagier³, Robert Bridgforth⁴, Gary J Williams⁵, Joanna M. Popov², Stanley J. Naides² and Andreas Reiff⁶, ¹Rheumatology, Children's Hospital of Los Angeles, Los Angeles, CA, ²Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ³Research Support, Alameda, Quest Diagnostics Alameda, Alameda, CA, ⁴quest diagnostics Nichols Institue, clemente, CA, ⁵Nicolas Institue, Quest Diagnostics, San Juan Capistrano, CA, ⁶Childrens Hospital of Los Angeles, Los Angeles, CA
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disease. Currently, diagnosis is based on clinical assessment defined by the International League of…
Abstract Number: 71 • 2017 Pediatric Rheumatology Symposium
Consensus-based diagnostic approach to systemic juvenile idiopathic arthritis in Germany
Claas Hinze¹, Dirk Holzinger¹, Elke Lainka², Johannes Peter Haas³, Tilmann Kallinich⁴, Ulrich Neudorf², Helmut Wittkowski¹, Gerd Horneff⁵, Dirk Foell⁶ and PRO-KIND study group on SJIA, ¹Department of Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany, ²University of Essen, Essen, Germany, ³Center for Pediatric and Adolescent Rheumatology Garmisch-Partenkirchen, Garmisch-Partenkirchen, Germany, ⁴Charite, University Medicine Berlin, Berlin, Germany, ⁵Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ⁶Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is currently classified by the International League of Associations for Rheumatology (ILAR) classification criteria. It is characterized by severe…
Abstract Number: 2851 • 2016 ACR/ARHP Annual Meeting
An Antigen Microarray to Rule-out Systemic Lupus Erythematosus, the SLE-Key® Rule-out Test, Performs Well As an Aid in Clinical Practice
Donald Massenburg, Justine Oldenberg, Amanda Sell, Tristan Krause and Alvin F. Wells, Rheumatology and Immunotherapy Center, Franklin, WI
Background/Purpose: The SLE-key® test to Rule Out lupus was developed by ImmunArray Ltd using serum samples of 246 SLE patients and 252 self-declared healthy controls.…
Abstract Number: 3106 • 2016 ACR/ARHP Annual Meeting
A Simple Test for Assessing and Monitoring SLE Disease Activity Status
Chaim Putterman¹, Michael Rowe², Joseph Barten Legutki², Theodore M. Tarasow² and Kathryn Sykes², ¹Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ²HealthTell, Inc, san ramon, CA
Background/Purpose: SLE patients can experience chronically active disease, remissions and flares, or long periods of quiescence. Accurately assessing disease activity is crucial for prescribing appropriate…
Abstract Number: 218 • 2016 ACR/ARHP Annual Meeting
Accuracy of Humasens-Plus Point-of-Care Uric Acid Meter Using Capillary Blood Obtained By Fingertip Puncture
Stephanie Fabre¹, Jean-Marie Launay¹, Jean-François Gautier¹, Adam Platt², Jeffrey N. Miner³, Glen Hughes², Pascal Richette⁴ and Thomas Bardin¹, ¹Hôpital Lariboisière, Paris, France, ²AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ³Discovery Biology, Ardea Biosciences, Inc., San Diego, CA, ⁴Fédération de Rhumatologie, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France
Background/Purpose: A key factor in the success of gout management is the long-term lowering of serum uric acid (sUA) levels below predetermined targets (5 or…
Abstract Number: 494 • 2016 ACR/ARHP Annual Meeting
Sensitivity and Specificity of 14-3-3η, Anti-CEP-1 and Anti-Sa Antibodies in a Cohort of Seronegative and Suspected Rheumatoid Arthritis (RA) Patients from a Community Rheumatology Practice
Dmitry Karayev¹, Guoqiu Shen¹, Yvonne Lam¹, Andrew Rimmer¹, Nayan Lal¹, Eugene Karayev¹, Kristine Azarraga¹, Ronald A. Blum¹, Allan L. Metzger¹, Robert I. Morris¹ and Arash A. Horizon², ¹Rheumatology Diagnostics Laboratory, Inc. (RDL), Los Angeles, CA, ²Center for Rheumatology Medical Group, Los Angeles, CA
Background/Purpose: RA is the most common autoimmune inflammatory joint disease, affecting up to 1% of the world population. Detection of antibodies, specifically against IgM rheumatoid…
Abstract Number: 512 • 2016 ACR/ARHP Annual Meeting
Anti-Cyclic Citrullinated Protein Antibody (ACPA) Positivity in General Population and Follow-up Results for ACPA Positive Persons
Yoichiro Haji¹, Ryo Rokutanda², Mitsumasa Kishimoto² and Masato Okada², ¹Rheumatology, Daido Hospital, Nagoya, Japan, ²Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: To evaluate anti-cyclic citrullinated protein antibody positivity in the general population and to identify its prognosis. Methods: Anti-cyclic citrullinated protein antibody (ACPA) were measured…
Abstract Number: 791 • 2016 ACR/ARHP Annual Meeting
The International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns (ICAP) Initiative – Update and Its Impact
Edward K.L. Chan¹, Jan Damoiseaux², Gabriel Carballo³, Karsten Conrad⁴, Wilson de Melo Cruvinel⁵, Paulo Francescantonio⁵, Marvin J. Fritzler⁶, Ignacio Garcia-De La Torre⁷, Manfred Herold⁸, Tsuneyo Mimori⁹, Minoru Satoh¹⁰, Carlos Von Muhlen¹¹, Luis E C Andrade¹² and representing committee and translation team members, ¹Dept of Oral Biology, University of Florida, Gainesville, FL, ²Central Diagnostic Laboratory, Maastricht University Medical Center, Maastricht, Netherlands, ³Hospital Carlos G. Durand, Buenos Aires, Argentina, ⁴Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, ⁵Pontifícia Universidade Católica de Goiás, Goiânia, Brazil, ⁶Medicine, University of Calgary, Calgary, AB, Canada, ⁷Immunology & Rheumatology, Centro de Est. de Invest. Bas. y Clin., S.C., Guadalajara, JAL, Mexico, ⁸Medical University of Innsbruck, Innsbruck, Austria, ⁹Kyoto University Graduate School of Medicine, Kyoto, Japan, ¹⁰Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹¹Rheumatology, Rheuma Clinic Dr. von Muhlen, Porto Alegre, Brazil, ¹²Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: The indirect immunofluorescence (IIF) pattern observed in the antinuclear antibody (ANA) test provides an initial assessment of autoantibody responses in candidate patients who have…
Abstract Number: 815 • 2016 ACR/ARHP Annual Meeting
The Novel Anti-BICD2 Autoantibody Potentially Predicts a Favorable Disease Course in SSc
Johannes Schulte-Pelkum¹, Daniel Wirtz¹, Petra Budde¹, Hans-Dieter Zucht¹, Peter Schulz-Knappe¹, Prof. Dr. Matthias Schneider², Suzana Jordan³, Oliver Distler³, Britta Maurer³ and Nicolas Hunzelmann⁴, ¹Protagen AG, Dortmund, Germany, ²Department of Rheumatology, Univ. Duesseldorf, Duesseldorf, Germany, ³Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁴Department of Dermatology, University of Cologne, Cologne, Germany
Background/Purpose: To evaluate clinical associations of our recently discovered systemic sclerosis-specific auto-antigen BICD2 in clinically well characterized systemic sclerosis (SSc) cohorts from two tertiary referral…
Abstract Number: 853 • 2016 ACR/ARHP Annual Meeting
Clinical Associations of Anti-Eukaryotic Initiation Factor 2B (anti-eIF2B) Antibodies in a Large Cohort of Patients with Anti-Nuclear Antibody Negative Systemic Sclerosis
John Pauling^1,2, Hui Lu¹, Zoe Betteridge^1,2, Gloria Salazar³, Shervin Assassi³, Maureen D Mayes³ and Neil J. McHugh^1,4, ¹Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ²Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁴Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: Autoantibodies can be characterized in up to 95% of patients with systemic sclerosis (SSc) and provide enormous diagnostic and prognostic value in the clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.